Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study.

Coxson HO, Dirksen A, Edwards LD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Crim C, Duvoix A, Fauerbach PN, Lomas DA, Macnee W, Mayer RJ, Miller BE, Müller NL, Rennard SI, Silverman EK, Tal-Singer R, Wouters EF, Vestbo J; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators.

Lancet Respir Med. 2013 Apr;1(2):129-36. doi: 10.1016/S2213-2600(13)70006-7. Epub 2013 Feb 1.

PMID:
24429093
2.

Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team.

Vestbo J, Agusti A, Wouters EF, Bakke P, Calverley PM, Celli B, Coxson H, Crim C, Edwards LD, Locantore N, Lomas DA, MacNee W, Miller B, Rennard SI, Silverman EK, Yates JC, Tal-Singer R; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Study Investigators.

Am J Respir Crit Care Med. 2014 May 1;189(9):1022-30. doi: 10.1164/rccm.201311-2006PP.

PMID:
24552242
3.

Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease.

Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards LD, Lomas DA, Miller BE, Reynaert N, Tal-Singer R, Wouters EF, Agustí A, Fabbri LM, Rames A, Visvanathan S, Rennard SI, Jones P, Parmar H, MacNee W, Wolff G, Silverman EK, Mayer RJ, Pillai SG; TESRA and ECLIPSE Investigators.

Am J Respir Crit Care Med. 2013 Oct 15;188(8):948-57. doi: 10.1164/rccm.201302-0247OC.

PMID:
23947473
4.

Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study.

Miniati M, Monti S, Basta G, Cocci F, Fornai E, Bottai M.

Respir Res. 2011 Mar 30;12:37. doi: 10.1186/1465-9921-12-37.

5.

Emphysema distribution and annual changes in pulmonary function in male patients with chronic obstructive pulmonary disease.

Tanabe N, Muro S, Tanaka S, Sato S, Oguma T, Kiyokawa H, Takahashi T, Kinose D, Hoshino Y, Kubo T, Ogawa E, Hirai T, Mishima M.

Respir Res. 2012 Apr 18;13:31. doi: 10.1186/1465-9921-13-31.

6.

Soluble receptor for advanced glycation end-products and progression of airway disease.

Iwamoto H, Gao J, Pulkkinen V, Toljamo T, Nieminen P, Mazur W.

BMC Pulm Med. 2014 Apr 24;14:68. doi: 10.1186/1471-2466-14-68.

7.

Clinical and Immunological Factors in Emphysema Progression. Five-Year Prospective Longitudinal Exacerbation Study of Chronic Obstructive Pulmonary Disease (LES-COPD).

Bhavani S, Tsai CL, Perusich S, Hesselbacher S, Coxson H, Pandit L, Corry DB, Kheradmand F.

Am J Respir Crit Care Med. 2015 Nov 15;192(10):1171-8. doi: 10.1164/rccm.201504-0736OC.

8.

Gender differences in the severity of CT emphysema in COPD.

Dransfield MT, Washko GR, Foreman MG, Estepar RS, Reilly J, Bailey WC.

Chest. 2007 Aug;132(2):464-70. Epub 2007 Jun 15.

PMID:
17573503
9.

Epidemiology, radiology, and genetics of nicotine dependence in COPD.

Kim DK, Hersh CP, Washko GR, Hokanson JE, Lynch DA, Newell JD, Murphy JR, Crapo JD, Silverman EK; COPD Gene Investigators.

Respir Res. 2011 Jan 13;12:9. doi: 10.1186/1465-9921-12-9.

10.

Identification of chronic obstructive pulmonary disease in lung cancer screening computed tomographic scans.

Mets OM, Buckens CF, Zanen P, Isgum I, van Ginneken B, Prokop M, Gietema HA, Lammers JW, Vliegenthart R, Oudkerk M, van Klaveren RJ, de Koning HJ, Mali WP, de Jong PA.

JAMA. 2011 Oct 26;306(16):1775-81. doi: 10.1001/jama.2011.1531.

PMID:
22028353
11.

Persistent airway inflammation and emphysema progression on CT scan in ex-smokers observed for 4 years.

Miller M, Cho JY, Pham A, Friedman PJ, Ramsdell J, Broide DH.

Chest. 2011 Jun;139(6):1380-1387. doi: 10.1378/chest.10-0705. Epub 2010 Oct 21.

12.

Diagnosis of chronic obstructive pulmonary disease in lung cancer screening Computed Tomography scans: independent contribution of emphysema, air trapping and bronchial wall thickening.

Mets OM, Schmidt M, Buckens CF, Gondrie MJ, Isgum I, Oudkerk M, Vliegenthart R, de Koning HJ, van der Aalst CM, Prokop M, Lammers JW, Zanen P, Mohamed Hoesein FA, Mali WP, van Ginneken B, van Rikxoort EM, de Jong PA.

Respir Res. 2013 May 27;14:59. doi: 10.1186/1465-9921-14-59.

13.

Comparison of clinical features between non-smokers with COPD and smokers with COPD: a retrospective observational study.

Zhang J, Lin XF, Bai CX.

Int J Chron Obstruct Pulmon Dis. 2014;9:57-63. doi: 10.2147/COPD.S52416. Epub 2014 Jan 8.

14.

Computed tomography-quantified emphysema distribution is associated with lung function decline.

Mohamed Hoesein FA, van Rikxoort E, van Ginneken B, de Jong PA, Prokop M, Lammers JW, Zanen P.

Eur Respir J. 2012 Oct;40(4):844-50. Epub 2012 Feb 9.

15.

Longitudinal study of spatially heterogeneous emphysema progression in current smokers with chronic obstructive pulmonary disease.

Tanabe N, Muro S, Sato S, Tanaka S, Oguma T, Kiyokawa H, Takahashi T, Kinose D, Hoshino Y, Kubo T, Hirai T, Mishima M.

PLoS One. 2012;7(9):e44993. doi: 10.1371/journal.pone.0044993. Epub 2012 Sep 18. Erratum in: PLoS One. 2012;7(11). doi: 10.1371/annotation/793db8a1-2d43-45bd-9ad5-8dac83195b15.

16.

Plasma pro-surfactant protein B and lung function decline in smokers.

Leung JM, Mayo J, Tan W, Tammemagi CM, Liu G, Peacock S, Shepherd FA, Goffin J, Goss G, Nicholas G, Tremblay A, Johnston M, Martel S, Laberge F, Bhatia R, Roberts H, Burrowes P, Manos D, Stewart L, Gingras M, Pasian S, Tsao MS, Lam S, Sin DD; Pan-Canadian Early Lung Cancer Study Group.

Eur Respir J. 2015 Apr;45(4):1037-45. doi: 10.1183/09031936.00184214. Epub 2015 Jan 22. Erratum in: Eur Respir J. 2016 Sep;48(3):962.

17.

Circulating soluble receptor for advanced glycation end products (sRAGE) as a biomarker of emphysema and the RAGE axis in the lung.

Yonchuk JG, Silverman EK, Bowler RP, Agustí A, Lomas DA, Miller BE, Tal-Singer R, Mayer RJ.

Am J Respir Crit Care Med. 2015 Oct 1;192(7):785-92. doi: 10.1164/rccm.201501-0137PP. Review.

PMID:
26132989
18.

Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality.

Williams MC, Murchison JT, Edwards LD, Agustí A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Vestbo J, Wouters E, Yates JC, van Beek EJ, Newby DE, MacNee W; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators.

Thorax. 2014 Aug;69(8):718-23. doi: 10.1136/thoraxjnl-2012-203151. Epub 2014 Jan 28.

PMID:
24473329
19.

Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study.

Singh D, Edwards L, Tal-Singer R, Rennard S.

Respir Res. 2010 Jun 15;11:77. doi: 10.1186/1465-9921-11-77.

20.

Reduced Bone Density and Vertebral Fractures in Smokers. Men and COPD Patients at Increased Risk.

Jaramillo JD, Wilson C, Stinson DS, Lynch DA, Bowler RP, Lutz S, Bon JM, Arnold B, McDonald ML, Washko GR, Wan ES, DeMeo DL, Foreman MG, Soler X, Lindsay SE, Lane NE, Genant HK, Silverman EK, Hokanson JE, Make BJ, Crapo JD, Regan EA; COPDGene Investigators.

Ann Am Thorac Soc. 2015 May;12(5):648-56. doi: 10.1513/AnnalsATS.201412-591OC. Erratum in: Ann Am Thorac Soc. 2015 Jul;12(7):1112. Stinson, Douglas J [corrected to Douglas S].

Supplemental Content

Support Center